CytomX Historical Balance Sheet

CTMX Stock

USD 0.59 0.03 4.84%

Trend analysis of CytomX Therapeutics balance sheet accounts such as Short Long Term Debt Total of 16 M, Other Current Liabilities of 17.6 M or Total Current Liabilities of 83.7 M provides information on CytomX Therapeutics' total assets, liabilities, and equity, which is the actual value of CytomX Therapeutics to its prevalent stockholders. By breaking down trends over time using CytomX Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining CytomX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CytomX Therapeutics is a good buy for the upcoming year.

CytomX Therapeutics Inventory

0.86

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

About CytomX Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of CytomX Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. CytomX Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of CytomX Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which CytomX currently owns. An asset can also be divided into two categories, current and non-current.

CytomX Therapeutics Balance Sheet Chart

At this time, CytomX Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Intangible Assets is likely to rise to about 1 M in 2025, whereas Total Assets are likely to drop slightly above 114.5 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Capital Surpluse

Add Fundamental

Total Assets

Total assets refers to the total amount of CytomX Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in CytomX Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on CytomX Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CytomX Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from CytomX Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Intangible Assets is likely to rise to about 1 M in 2025, whereas Total Assets are likely to drop slightly above 114.5 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	18.1M	14.0M	9.4M	16.0M
Total Assets	260.9M	201.8M	120.5M	114.5M

Short Long Term Debt Total Total Assets

CytomX Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.87	0.85	0.64	0.69	0.81	0.57	0.52	-0.92	-0.41	0.7	0.93	0.61	-0.22	0.41	1.0	0.18	0.19	0.19	0.16	0.87	0.85	-0.78	0.78	0.25	0.85
Short Long Term Debt Total	0.87		0.68	0.49	0.8	0.67	0.48	0.39	-0.76	-0.33	0.84	0.75	0.55	-0.03	0.42	0.87	0.15	0.06	0.06	-0.04	0.85	0.61	-0.86	0.73	0.24	0.66
Other Current Liab	0.85	0.68		0.85	0.44	0.79	0.8	0.75	-0.79	-0.73	0.39	0.82	0.81	-0.3	0.26	0.81	0.31	-0.09	-0.09	0.53	0.73	0.65	-0.79	0.76	0.64	0.88
Total Current Liabilities	0.64	0.49	0.85		0.1	0.78	0.73	0.98	-0.5	-0.92	0.15	0.55	0.71	-0.33	0.24	0.58	0.5	-0.15	-0.15	0.76	0.68	0.46	-0.76	0.72	0.8	0.82
Total Stockholder Equity	0.69	0.8	0.44	0.1		0.39	0.16	-0.04	-0.6	0.01	0.77	0.57	0.24	0.06	0.26	0.74	-0.33	0.07	0.07	-0.26	0.64	0.35	-0.62	0.41	-0.05	0.28
Other Liab	0.81	0.67	0.79	0.78	0.39		0.52	0.72	-0.67	-0.7	0.38	0.68	0.54	-0.04	0.29	0.8	0.34	-0.2	-0.2	0.53	0.85	0.68	-0.81	0.73	0.5	0.87
Property Plant And Equipment Net	0.57	0.48	0.8	0.73	0.16	0.52		0.68	-0.51	-0.69	0.13	0.58	0.99	-0.35	0.51	0.51	0.21	-0.07	-0.07	0.5	0.4	0.45	-0.59	0.73	0.77	0.68
Current Deferred Revenue	0.52	0.39	0.75	0.98	-0.04	0.72	0.68		-0.37	-0.93	0.04	0.42	0.66	-0.34	0.22	0.46	0.54	-0.15	-0.15	0.79	0.6	0.37	-0.69	0.65	0.82	0.74
Net Debt	-0.92	-0.76	-0.79	-0.5	-0.6	-0.67	-0.51	-0.37		0.27	-0.69	-1.0	-0.55	0.33	-0.36	-0.91	-0.29	-0.26	-0.26	-0.08	-0.66	-0.88	0.6	-0.71	-0.12	-0.8
Retained Earnings	-0.41	-0.33	-0.73	-0.92	0.01	-0.7	-0.69	-0.93	0.27		0.05	-0.32	-0.66	0.24	-0.15	-0.35	-0.45	0.46	0.46	-0.86	-0.52	-0.17	0.72	-0.58	-0.95	-0.64
Accounts Payable	0.7	0.84	0.39	0.15	0.77	0.38	0.13	0.04	-0.69	0.05		0.66	0.21	0.15	0.2	0.72	0.05	0.33	0.33	-0.3	0.58	0.53	-0.59	0.41	-0.17	0.37
Cash	0.93	0.75	0.82	0.55	0.57	0.68	0.58	0.42	-1.0	-0.32	0.66		0.62	-0.36	0.4	0.91	0.3	0.26	0.26	0.13	0.65	0.88	-0.62	0.74	0.19	0.82
Non Current Assets Total	0.61	0.55	0.81	0.71	0.24	0.54	0.99	0.66	-0.55	-0.66	0.21	0.62		-0.31	0.54	0.55	0.18	-0.07	-0.07	0.46	0.44	0.48	-0.63	0.77	0.74	0.69
Non Currrent Assets Other	-0.22	-0.03	-0.3	-0.33	0.06	-0.04	-0.35	-0.34	0.33	0.24	0.15	-0.36	-0.31		-0.4	-0.17	-0.4	-0.21	-0.21	-0.19	-0.04	-0.24	0.07	-0.33	-0.27	-0.29
Other Assets	0.41	0.42	0.26	0.24	0.26	0.29	0.51	0.22	-0.36	-0.15	0.2	0.4	0.54	-0.4		0.39	-0.1	0.11	0.11	0.01	0.26	0.38	-0.29	0.75	0.21	0.36
Cash And Short Term Investments	1.0	0.87	0.81	0.58	0.74	0.8	0.51	0.46	-0.91	-0.35	0.72	0.91	0.55	-0.17	0.39		0.11	0.2	0.2	0.11	0.87	0.84	-0.76	0.75	0.19	0.82
Net Receivables	0.18	0.15	0.31	0.5	-0.33	0.34	0.21	0.54	-0.29	-0.45	0.05	0.3	0.18	-0.4	-0.1	0.11		-0.02	-0.02	0.33	0.2	0.32	-0.28	0.23	0.32	0.47
Good Will	0.19	0.06	-0.09	-0.15	0.07	-0.2	-0.07	-0.15	-0.26	0.46	0.33	0.26	-0.07	-0.21	0.11	0.2	-0.02		1.0	-0.35	-0.06	0.4	0.24	-0.07	-0.5	-0.03
Common Stock Total Equity	0.19	0.06	-0.09	-0.15	0.07	-0.2	-0.07	-0.15	-0.26	0.46	0.33	0.26	-0.07	-0.21	0.11	0.2	-0.02	1.0		-0.35	-0.06	0.4	0.24	-0.07	-0.5	-0.03
Common Stock Shares Outstanding	0.16	-0.04	0.53	0.76	-0.26	0.53	0.5	0.79	-0.08	-0.86	-0.3	0.13	0.46	-0.19	0.01	0.11	0.33	-0.35	-0.35		0.19	0.04	-0.4	0.31	0.81	0.41
Short Term Investments	0.87	0.85	0.73	0.68	0.64	0.85	0.4	0.6	-0.66	-0.52	0.58	0.65	0.44	-0.04	0.26	0.87	0.2	-0.06	-0.06	0.19		0.62	-0.86	0.69	0.33	0.78
Non Current Liabilities Total	0.85	0.61	0.65	0.46	0.35	0.68	0.45	0.37	-0.88	-0.17	0.53	0.88	0.48	-0.24	0.38	0.84	0.32	0.4	0.4	0.04	0.62		-0.42	0.64	0.0	0.83
Inventory	-0.78	-0.86	-0.79	-0.76	-0.62	-0.81	-0.59	-0.69	0.6	0.72	-0.59	-0.62	-0.63	0.07	-0.29	-0.76	-0.28	0.24	0.24	-0.4	-0.86	-0.42		-0.71	-0.62	-0.7
Other Current Assets	0.78	0.73	0.76	0.72	0.41	0.73	0.73	0.65	-0.71	-0.58	0.41	0.74	0.77	-0.33	0.75	0.75	0.23	-0.07	-0.07	0.31	0.69	0.64	-0.71		0.51	0.81
Other Stockholder Equity	0.25	0.24	0.64	0.8	-0.05	0.5	0.77	0.82	-0.12	-0.95	-0.17	0.19	0.74	-0.27	0.21	0.19	0.32	-0.5	-0.5	0.81	0.33	0.0	-0.62	0.51		0.48
Total Liab	0.85	0.66	0.88	0.82	0.28	0.87	0.68	0.74	-0.8	-0.64	0.37	0.82	0.69	-0.29	0.36	0.82	0.47	-0.03	-0.03	0.41	0.78	0.83	-0.7	0.81	0.48

Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	358.7M	339.4M	260.9M	201.8M	120.5M	114.5M
Short Long Term Debt Total	24.9M	18.1M	18.1M	14.0M	9.4M	16.0M
Other Current Liab	19.9M	30.6M	24.5M	17.6M	12.3M	17.6M
Total Current Liabilities	100.9M	106.3M	152.6M	155.9M	85.8M	83.7M
Total Stockholder Equity	49.8M	89.4M	(85.8M)	(47.4M)	(456K)	(433.2K)
Other Liab	179.7M	186.3M	125.7M	180.1M	207.1M	151.2M
Property Plant And Equipment Net	29.4M	25.3M	21.0M	16.2M	10.6M	14.6M
Current Deferred Revenue	74.9M	69.3M	121.3M	132.3M	67.2M	58.9M
Net Debt	(167.0M)	(187.5M)	(175.6M)	(3.2M)	(28.7M)	(30.1M)
Retained Earnings	(450.1M)	(533.7M)	(722.9M)	(723.4M)	(691.6M)	(657.0M)
Accounts Payable	3.0M	2.8M	2.8M	1.5M	1.1M	1.0M
Cash	191.9M	205.5M	193.7M	17.2M	38.1M	36.1M
Non Current Assets Total	34.7M	29.1M	23.8M	18.9M	13.2M	19.1M
Non Currrent Assets Other	(3.4M)	(3.7M)	(3.6M)	1M	1.1M	1.1M
Other Assets	2.9M	25.6M	1.8M	944K	1.1M	1.0M
Cash And Short Term Investments	316.1M	305.2M	193.7M	174.5M	100.6M	95.6M
Net Receivables	798K	790K	36.0M	3.4M	3.1M	5.5M
Common Stock Shares Outstanding	46.1M	64.1M	65.7M	73.8M	84.7M	52.6M
Short Term Investments	107.7M	124.3M	99.7M	157.3M	62.6M	113.7M
Liabilities And Stockholders Equity	358.7M	339.4M	260.9M	201.8M	120.5M	114.5M
Non Current Liabilities Total	207.9M	143.7M	194.0M	93.3M	35.2M	33.5M
Other Current Assets	14.2M	4.3M	7.5M	5.0M	3.6M	5.7M
Other Stockholder Equity	500.0M	623.3M	637.1M	675.9M	691.1M	725.6M
Total Liab	308.9M	250.0M	346.6M	249.2M	121.0M	240.3M
Property Plant And Equipment Gross	29.4M	25.3M	21.0M	30.9M	26.8M	17.4M
Total Current Assets	324.0M	310.3M	237.1M	182.9M	107.3M	101.9M
Accumulated Other Comprehensive Income	(47K)	(242K)	10K	95K	27K	28.4K
Short Term Debt	3.2M	3.6M	4.1M	4.6M	5.1M	4.8M
Intangible Assets	1.2M	1.0M	875K	729K	583K	1.0M
Property Plant Equipment	6.9M	32.8M	7.0M	6.0M	6.9M	8.3M
Net Tangible Assets	48.9M	47.7M	87.4M	(2.4M)	(2.8M)	(2.7M)
Retained Earnings Total Equity	(417.2M)	(450.1M)	(533.7M)	(623.6M)	(561.2M)	(533.1M)
Capital Surpluse	446.0M	468.3M	500.0M	623.3M	716.8M	474.2M
Non Current Liabilities Other	207.9M	143.7M	262M	3.9M	4.1M	3.9M
Net Invested Capital	49.8M	89.4M	(85.8M)	(47.4M)	(456K)	(433.2K)
Net Working Capital	223.1M	204.0M	84.5M	27.0M	21.5M	20.5M
Capital Lease Obligations	24.9M	21.7M	18.1M	14.0M	9.4M	15.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytomX Historical Balance Sheet

CytomX Therapeutics Inventory

0.86

About CytomX Balance Sheet Analysis

CytomX Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

CytomX Therapeutics balance sheet Correlations

CytomX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytomX Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for CytomX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Common Stock Total Equity	+ 1.0	Good Will
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Current Deferred Revenue	+ 0.98	Total Current Liabilities
Cash	+ 0.93	Total Assets
Cash And Short Term Investments	+ 0.91	Cash

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.95	Retained Earnings
Retained Earnings	- 0.93	Current Deferred Revenue
Retained Earnings	- 0.92	Total Current Liabilities
Net Debt	- 0.92	Total Assets
Cash And Short Term Investments	- 0.91	Net Debt